Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer

BACKGROUND: Achieving robust responses with adoptive cell therapy for the treatment of the highly lethal pancreatic ductal adenocarcinoma (PDA) has been elusive. We previously showed that T cells engineered to express a mesothelin-specific T cell receptor (TCR(Msln)) accumulate in autochthonous PDA,...

Descripción completa

Detalles Bibliográficos
Autores principales: Stromnes, Ingunn M, Hulbert, Ayaka, Rollins, Meagan R, Basom, Ryan S, Delrow, Jeffrey, Bonson, Patrick, Burrack, Adam L, Hingorani, Sunil R, Greenberg, Philip D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883283/
https://www.ncbi.nlm.nih.gov/pubmed/35210305
http://dx.doi.org/10.1136/jitc-2021-003525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883283/
https://www.ncbi.nlm.nih.gov/pubmed/35210305
http://dx.doi.org/10.1136/jitc-2021-003525

Ejemplares similares